Evidence map›Paper›PMID 30830754›Full record

ArticleBioconjugate chemistry2019

Dual Toll-Like Receptor Targeting Liposomal Spherical Nucleic Acids.

Jennifer R Ferrer, Jason A Wertheim, Chad A Mirkin

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Combined integrin αJournal of nanobiotechnology · 2021
    Article
  8. Article
  9. Article
  10. Review
  11. The chemical biology of IL-12 productionRSC chemical biology · 2020
    Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jennifer R FerrerDepartment of Chemistry , Northwestern University , Evanston , Illinois 60208 , United States.ORCID 0000-0001-8960-8861
Jason A WertheimDepartment of Surgery , Northwestern Feinberg School of Medicine , Chicago , Illinois 60611 , United States.ORCID 0000-0001-5680-1067
Chad A MirkinDepartment of Chemistry , Northwestern University , Evanston , Illinois 60208 , United States.ORCID 0000-0002-6634-7627
Northwestern University · US

Funding

Project 3: Spherical Nucleic Acids as Immunotherapeutic Agents for Prostate CancerU54CA199091 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MIRKIN, CHAD A. · 2015 to 2019
$11.7M
Mentoring For Success: Developing Fundamental Skills For Biomedical ResearchR25GM079300 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCGEE, RICHARD · 2007 to 2020
$6.6M
Chemistry of Life Processes Predoctoral Training ProgramT32GM105538 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2013 to 2022
$2.7M
Optimization and control of hepatocyte activity via biofunctional modificationK08DK101757 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WERTHEIM, JASON A · 2014 to 2018
$777k
Tailoring liposomal spherical nucleic acid nanoparticles for biological and therapeutic potencyF31GM119392 · NIGMS · NORTHWESTERN UNIVERSITY · PI FERRER, JENNIFER RACHEL · 2016 to 2017
$76k
NCI NIH HHS U54 CA199091NIDDK NIH HHS K08 DK101757NIGMS NIH HHS F31 GM119392NIGMS NIH HHS R25 GM079300NIGMS NIH HHS T32 GM105538
6 · The paper itself

Abstract

Liposomal spherical nucleic acids (LSNAs) are a class of nanomaterial used broadly for biomedical applications. Their intrinsic capacity to rapidly enter cells and engage cell surface and intracellular ligands stems from their unique three-dimensional architecture, which consists of densely packed and uniformly oriented oligonucleotides on the surface of a liposomal core. Such structures are promising for therapeutics because they can carry chemical cargo within the lipid core in addition to the nucleic acids that define them, in principle enabling delivery of multiple signals to a single cell. On the basis of these traits, we have designed novel dual-targeting LSNAs that deliver a nucleic acid specific for TLR9 inhibition and a small molecule (TAK-242) that inhibits TLR4. Toll-like receptors (TLRs) play a large role in pathogen recognition and disease initiation, and TLR subtypes are differentially located within the lipid membranes of the cell surface and within intracellular endosomes. Oftentimes, in acute or chronic inflammatory conditions, multiple TLRs are activated, leading to stimulation of distinct, and sometimes overlapping, downstream pathways. As such, these inflammatory conditions may respond to attenuation of more than one initiating receptor. We show that dual targeting LSNAs, comprised of unilamellar liposomal cores, the INH-18 oligonucleotide sequence, and TAK-242 robustly inhibit TLR-9 and TLR-4 respectively, in engineered TLR reporter cells and primary mouse peritoneal macrophages. Importantly, the LSNAs exhibit up to a 10- and a 1000-fold increase, respectively, in TLR inhibition compared to the linear sequence and TAK-242 alone. Moreover, the timing of delivery is shown to be a critical factor in effecting TLR-inhibition, with near-complete TLR-4 inhibition occurring when cells were pretreated with SNAs for 4 h prior to stimulation. The most pronounced effect observed from this approach is the benefit of delivering the small molecule within the SNA via the receptor-mediated internalization pathway common to SNAs.

Indexed as

LiposomesAnimalsCytokinesHEK293 CellsHumansInflammation MediatorsMacrophages, PeritonealMiceNucleic AcidsToll-Like ReceptorsCytokinesInflammation MediatorsLiposomesNucleic AcidsToll-Like Receptors

Identifiers

PMID30830754
PMCPMC6446553
OpenAlexW2919122975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.